Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GSK3915393 versus placebo in idiopathic pulmonary fibrosis
NL-OMON60466Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing GSK3915393 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Started Nov 2024; status: completed.
02
Drugs
GSK3915393
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON60466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60466.